Table 2.
Medical anamneses of European healthcare workers receiving the AstraZeneca COVID-19 vaccine, February–March 2021.
| Variable | <35 Years-Old | 35–49 Years-Old | >49 Years-Old | Total | Sig. 1 | ||
|---|---|---|---|---|---|---|---|
| Chronic Illness | Asthma | 3 (5.9%) | 0 (0%) | 1 (5.6%) | 4 (4.3%) | 0.640 | |
| Allergy | 0 (0%) | 0 (0%) | 1 (5.6%) | 1 (1.1%) | 0.196 | ||
| Bone Disease | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 1.000 | ||
| Chronic Hypertension | 0 (0%) | 0 (0%) | 1 (5.6%) | 1 (1.1%) | 0.196 | ||
| Neurologic Disease | 0 (0%) | 1 (4.3%) | 2 (11.1%) | 3 (3.3%) | 0.049 | ||
| Psychologic Distress | 0 (0%) | 1 (4.3%) | 1 (5.6%) | 2 (2.2%) | 0.196 | ||
| Rheumatoid Arthritis | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 1.000 | ||
| Thyroid Disease | 3 (5.9%) | 2 (8.7%) | 0 (0%) | 5 (5.4%) | 0.590 | ||
| Total | 6 (11.8%) | 4 (17.4%) | 4 (22.2%) | 14 (15.2%) | 0.462 | ||
| Medical Treatment | Antidepressants | 3 (5.9%) | 2 (8.7%) | 3 (16.7%) | 8 (8.7%) | 0.367 | |
| Antiepileptics | 0 (0%) | 1 (4.3%) | 0 (0%) | 1 (1.1%) | 0.446 | ||
| Antihypertensive | 0 (0%) | 1 (4.3%) | 0 (0%) | 1 (1.1%) | 0.446 | ||
| Contraceptives | 3 (5.9%) | 0 (0%) | 1 (5.6%) | 4 (4.3%) | 0.640 | ||
| Immunosuppressive | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 1.000 | ||
| Pain killers | 0 (0%) | 0 (0%) | 1 (5.6%) | 1 (1.1%) | 0.196 | ||
| Thyroid Hormone | 3 (5.9%) | 3 (13%) | 0 (0%) | 6 (6.5%) | 0.216 | ||
| Total | 10 (19.6%) | 7 (30.4%) | 4 (22.2%) | 21 (22.8%) | 0.626 | ||
| COVID-19 anamneses | Previous Infection | 4 (7.8%) | 3 (13%) | 1 (5.6%) | 8 (8.7%) | 0.692 | |
| Exposure | 19 (37.3%) | 11 (47.8%) | 5 (27.8%) | 35 (38%) | 0.416 | ||
| Vaccine Dosage | One Dose | 51 (56%) | 22 (24.2%) | 18 (19.8%) | 91 (98.9%) | 0.446 | |
| Two Doses | 0 (0%) | 1 (100%) | 0 (0%) | 1 (1.1%) | |||
1 Chi-squared test and Fisher’s exact test were used with a significance level (Sig.) of <0.05.